- Home
- FBRX vs ITIC Comparison
FBRX vs ITIC Comparison
Compare FBRX & ITIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FBRX | ITIC |
|---|---|---|
| Founded | N/A | 1972 |
| Country | United States | United States |
| Employees | N/A | 574 |
| Industry | Biotechnology: Pharmaceutical Preparations | Specialty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 487.2M | 443.2M |
| IPO Year | 2017 | 1995 |
Fundamental Metrics
Financial Performance| Metric | FBRX | ITIC |
|---|---|---|
| Price | $19.12 | $236.71 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $67.00 | N/A |
| AVG Volume (30 Days) | ★ 178.8K | 20.5K |
| Earning Date | 05-14-2026 | 05-04-2026 |
| Dividend Yield | N/A | ★ 4.43% |
| EPS Growth | ★ 61.30 | 13.02 |
| EPS | N/A | ★ 3.20 |
| Revenue | $36,000.00 | ★ $272,755,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $74.51 |
| Revenue Growth | N/A | ★ 5.60 |
| 52 Week Low | $7.78 | $190.20 |
| 52 Week High | $35.80 | $288.98 |
Technical Indicators
Market Signals| Indicator | FBRX | ITIC |
|---|---|---|
| Relative Strength Index (RSI) | 32.53 | 46.43 |
| Support Level | $18.18 | $229.64 |
| Resistance Level | $34.44 | $247.37 |
| Average True Range (ATR) | 2.09 | 6.05 |
| MACD | -0.22 | -0.48 |
| Stochastic Oscillator | 5.88 | 37.92 |
Price Performance
Historical ComparisonAbout FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.
About ITIC Investors Title Company
Investors Title Co operates in the title insurance and exchange services sectors. The Company has two reportable segments. The Company's primary business activity, and one of its reportable operating segments, is the issuance of residential and commercial title insurance through ITIC and NITIC. The company's second reportable operating segment is providing tax-deferred real property exchange services through its subsidiaries, Investors Title Exchange Corporation (ITEC) and Investors Title Accommodation Corporation (ITAC).